Publications

Here you can review available Corcept-sponsored publications.

 

Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses of products will receive FDA approval. Corcept does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

 

Access Corcept-sponsored publications below.

Filter by:

Endocrinology

2026

Investigating Endogenous Hypercortisolism Prevalence in a US Population with Resistant Hypertension: MOMENTUM Rationale and Design

Plutzky J, Taub PR, Bhatt DL, et al.

Endocrinology

2025

Relacorilant

Relacorilant or surgery improved hemostatic markers in Cushing syndrome

Simeoli C, Di Paola N, Stigliano A, et al

Endocrinology

2025

Mifepristone

Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment

DeFronzo RA, Fonseca V, Aroda VR, et al

Endocrinology

2025

Mifepristone

Identification of Endogenous Hypercortisolism and the Effect of Mifepristone Treatment in Patients With Difficult-to-Manage Diabetes: A Case Series

Lucci CP, McCoy G

Endocrinology

2025

Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes

Buse JB, Kahn SE, Aroda VR, et al.

Endocrinology

2024

Relacorilant

Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT Interval

Donegan DM, Pivonello R, Stigliano A, et al

Endocrinology

2024

Mifepristone

Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone

DeFronzo RA, Auchus RJ, Bancos I, et al

Endocrinology

2023

Difficult-to-Control Diabetes: Is Cortisol at Play

Roundtable Discussion

Endocrinology

2022

Relacorilant

Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

Pivonello R, Bancos I, Feelders RA, et al

Endocrinology

2022

Relacorilant

Peripheral glucocorticoid receptor antagonism by relacorilant with modest HPA axis disinhibition

Viho EMG, Kroon J, Feelders RA, et al

Endocrinology

2021

When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis

Aresta A, Soranna D, Giovanelli L, et al

Endocrinology

2021

Relacorilant

Hidden hypercortisolism: a too frequently neglected clinical condition

Giovanelli L, Aresta C, Favero V, et al.

Endocrinology

2021

Relacorilant

Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

Pivonello R, Bancos I, Feelders RA, et al

Endocrinology

2021

Mifepristone

Mifepristone as Bridge or Adjunct Therapy in the Management of Challenging Cushing Disease Cases

Chang AY, Mirfakhraee S, King EE, et al.

Endocrinology

2020

Mifepristone

Clinical Management of patients with Cushing Syndrome treated with mifepristone: consensus recommendations

Brown DR, East HE, Eilerman BS, et al.

Endocrinology

2019

Hypercortisolism in Newly Diagnosed Type 2 Diabetes: A Prospective Study of 384 Newly Diagnosed Patients

Steffensen C, Dekkers OM, Lyhne J, et al

Endocrinology

2019

Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-analysis

Elhassan YS, Alahdab F, Prete A, et al

Endocrinology

2018

Relacorilant

Assessment of Safety,Tolerability,Pharmacokinetics, and Pharmacological Effect of Orally Administered CORT125134: An Adaptive, Double-Blind, Randomized, Placebo-Controlled Phase 1 Clinical Study

Hunt H, Donaldson K, Strem M, et al.

Endocrinology

2017

Mifepristone

Evaluation of evidence of adrenal insufficiency in trials of normocortisolemic patients treated with mifepristone

Yuen KCJ, Moraitis A, Nguyen D

Endocrinology

2016

Mifepristone

Mifepristone improves octreotide efficacy in resistant ectopic Cushing’s syndrome

Moraitis AG, Auchus RJ

Endocrinology

2016

Prevalence of hypercortisolism in type 2 diabetes patients: a systematic review and meta-analysis

Steffensen C, Pereira AM, Dekkers OM, Jørgensen JOL

Endocrinology

2016

Prevalence of subclinical hypercortisolism in type 2 diabetic patients from the Rio de Janeiro Type 2 Diabetes Cohort Study

Costa DS, Conceição FL, Leite NC, Ferreira MT, Salles GF, Cardoso CRL

Endocrinology

2015

Mifepristone

Association between mifepristone dose, efficacy, and tolerability in patients with Cushing syndrome

Yuen KCJ, Williams G, Kushner H, Nguyen D

Endocrinology

2015

Mifepristone

Mifepristone and Cushing syndrome: A commentary

Kennedy L

Endocrinology

2015

Mifepristone

Persistent Weight Loss in Patients Treated With Mifepristone for Cushing's Syndrome: Results From the SEISMIC & Long-Term Extension Studies

Fein HG, Vaughan III B, Gross C, et al.

Endocrinology

2014

Long-Term Follow-Up in Adrenal Incidentalomas: An Italian Multicenter Study

Morelli V, Reimondo G, Giordano R, et al.

Endocrinology

2014

Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study

Di Dalmazi G, Vicennati V, Garelli S, et al.

Endocrinology

2014

Cortisol as a Marker for Increased Mortality in Patients with Incidental Adrenocortical Adenomas

Debono M, Bradburn M, Bull M, Harrison B, Ross RJ, Newell-Price J

Endocrinology

2014

Mifepristone

Global clinical response in Cushing’s syndrome patients treated with mifepristone

Katznelson L, Loriaux DL, Feldman D, et al.

Endocrinology

2013

Mifepristone

A new therapeutic approach in the medical treatment of Cushing’s syndrome: glucocorticoid receptor blockade with mifepristone

Fleseriu M, Molitch ME, Gross C, Schteingart DE, Vaughan TB, Biller BMK

Endocrinology

2013

Mifepristone

Improvement in insulin sensitivity during mifepristone treatment of Cushing syndrome: early and late effects.

Wallia A, Colleran K, Purnell JQ, et al.

Endocrinology

2012

Mifepristone

Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome

Fleseriu M, Biller BMK, Findling JW, et al.

Endocrinology

2001

Mifepristone

Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486)

Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D